QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immuron-reported-q1-sales-growth-of-34-on-prior-comparative-period

Sales Highlights (unaudited):Global• Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)Australia • Q1 sales AUD$...

 immuron-says-it-is-on-track-to-exceed-fy24-first-quarter-sales-to-request-end-of-phase-2-meeting-with-fda-for-imm-124e

US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTr...

 immuron-advances-fda-filings-and-preps-2025-launch-of-new-ibs-treatment-proibs-eyes-october-results-for-travelan-us-military-trial

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to p...

 immuron-says-2025-sales-growth-of-49-for-travelan-exceeded-projection

GlobalAnnual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior yearAustralia Annual s...

 reported-earlier-immurons-travelan-hits-record-aud53m-in-ytd-sales-up-46-yoy-and-86-in-north-america

GlobalImmuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2...

 immuron-says-global-sales-for-december-2024-quarter-totals-aud25m-up-70-on-prior-quarter

Sales of Travelan increased 90% to AUD $1.851 million during December 2024 Quarter compared to AUD $1.007 million for September...

 immuron-enters-new-research-collaboration-with-monash-university

After the results from this research agreement are known, the parties will negotiate in good faith (and without obligation) whe...

 immuron-submits-phase-2-study-report-to-fda-prepares-for-end-of-phase-2-meeting-takes-next-step-toward-phase-3-trial

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to a...

 immuron-announces-sales-unaudited-of-travelan-a15m-up-13-prior-quarter-an-otc-immune-supplement-targeting-pathogenic-bacteria-and-toxins-produced-in-the-gastrointestinal-tract

Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia • September 2024 Quarter AUD$1.0 million up 3%...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION